The UK has an incredible opportunity to improve patients’ lives through cannabis-based medicines for some of the most debilitating conditions, such as chronic pain. Celadon Pharmaceuticals Plc is at the forefront of building this new pharmaceutical sector. We have a simple approach: high-quality UK cultivation and API manufacturing, clinical trials, and R&D into cannabinoids. We …
For those leading the company, this has been a very personal mission to produce a high-quality trial for cannabis-based medicines. James Short (CEO and co-founder of Celadon Pharmaceuticals Plc) saw his sister’s experience of living with multiple sclerosis for years and also witnessed first-hand the potential benefits of cannabis-based medicines for her condition. James also …
Celadon Pharmaceuticals Plc’s CEO Jim Short featured discussing the new MHRA framework for UK domestic production of cannabis-based medicines. Celadon was proudly a pioneer in working with the regulators back in 2019-2020. The new framework indicates a truly pharmaceutical direction of travel for the UK. This is Celadon’s approach: pharma-grade products, breakthrough R&D and clinical …
Today Celadon announced its Interim Results for the six months ended 30 June 2022, a period of considerable development and growth for the company. Highlights include: – The completion of seven harvests of high THC cannabis – Formally requesting that the MHRA schedule an inspection of our facility for our GMP licence – The commencement …
Celadon has been published in the Birmingham Mail on 30th July 2022. Click here to read the full story.
Input your search keywords and press Enter.